Clinical Trial

A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to tolerability and safety of humanized CD19 CAR-T therapy with TLR2 in adult patients with acute B lymphoblastic leukemia/lymphoma who cannot tolerate intense chemotherapy at initial treatment. Participants will receive a single infusion of CD19 CAR-T and complete follow-ups over the next three years.
Trial Details
NCT Number NCT07335094
Lead Sponsor Zhujiang Hospital
Conditions B Lymphoblastic Leukemia/Lymphoma
Enrollment 60 participants
Start Date 2026-06-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-12